Rice University synthetic biologists created a device to demonstrate a new method that could slash the costs of creating wearable monitors for precision, automated drug dosing of chemotherapies and other drugs. Photo by Jeff Fitlow/Rice University

A team of Rice University researchers has built a technology that uses a $20 blood-glucose sensor to potentially automate dosing of practically any drug.

In a paper recently published in Nature, researchers in Caroline Ajo-Franklin’s lab shared that they were able to modify the inexpensive piece of equipment to detect afimoxifene, an estrogen inhibitor that is naturally produced by a patient’s body after taking the chemotherapy drug tamoxifen.

“The dream is to have technology similar to what’s available today for monitoring and treating variations in blood glucose, and have that be true for basically any drug,” said Ajo-Franklin, a bioscientist, cancer researcher and director of the Rice Synthetic Biology Institute in a press release from Rice University. “Millions of people use blood-glucose monitors every day. If we can use that same basic technology to monitor other drugs and biomarkers, we could move away from the one-size-fits-all dosing regimes that we’re stuck with today.”

The lead author of the study was postdoctoral research associate Rong Cai. She and the team tested more than 400 modified versions of the electron-releasing proteins (what creates the current that glucose monitors detect) until they found a version that reacted with afimoxifene. Essentially, they built an afimoxifene sensor that could reliably detect the presence of the drug.

According to Ajo-Franklin, her team is currently at work testing ways to identify drugs other than afimoxifene.

In a press release, Cai said, “The glucometer is the part that’s so well-developed. While our target is different, it’s just a matter of engineering and changing the protein on the inside. On the outside, everything will still be the same. You can still do the test with a strip or on your arm.”

Better still, she went on to say that because the signal is electrical, it can be sent to a phone or computer to be read and stored.

“That’s the part, that marriage between electricity and biology, that is very attractive,” Cai said.

Rice University synthetic biologists (from right to left) Caroline Ajo-Franklin, Chiagoziem Ngwadom and Rong Cai worked with Rice engineer Rafael Verduzco (left) to create and demonstrate a method of universalizing blood-glucose detection technology as a way of rapidly and inexpensively creating sensors that can monitor the dosing of chemotherapies and other drugs in real time. Photo by Jeff Fitlow/Rice University

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston foundation doles out $700K for Texas chemical research

fresh funding

Houston-based The Welch Foundation has issued $700,000 in additional funding to support chemical research through two of its newest grant programs.

The foundation has named the recipients of its Welch eXperimental (WelchX) Collaboration Retreat and Pilot Grants and the Welch Postdoctoral Fellows of the Life Sciences Research Foundation Grants.

The WelchX grants were awarded to teams of two Texas researchers who presented "innovative and collaborative ideas" addressing challenges in the clean energy space, according to the foundation.

Researchers from Texas universities gathered in Houston earlier this summer to discuss the theme “Chemical Research for Grand Challenges." They then paired off into nine teams and submitted proposals for the $100,000 pilot grants. The seven selected teams, several with ties to Houston, and their research topics include:

  • Yimo Han, Rice University, and Yuanyue Liu, The University of Texas at Austin, “Stabilizing Copper Electrocatalysts for CO2 Conversion”
  • Ognjen Miljanic, University of Houston, and Indrajit Srivastava, Texas Tech University, “Ping-Pong' Afterglow Luminescence in Self-Assembled Molecular Cubes”
  • Raúl Hernández Sánchez, Rice University, and Andy Thomas, Texas A&M University, “Accelerating Magnetic Resonance Imaging Contrast Agent Discovery via Rapid Injection NMR: Improving the Detection of Lithium for Disease Diagnostics”
  • Benjamin Janesko, Texas Christian University, and MD Masud Rana, Lamar University, “Cyber Twin Chemical Ensembles for Near-Infrared-Emitting Graphene Quantum Dot Therapeutics”
  • Ivan Korendovych, Baylor University, and Dino Villagrán, The University of Texas at El Paso, “Selective Bio-Inspired Electrochemical Probes for PFAS Analysis and Degradation”
  • Samantha Kristufek, Texas Tech University, and Kayla Green, Texas Christian University, “CIRCUIT: Critical Ion Recovery using Conductive and Ultrafiltration Intelligent Technology”
  • Fang Xu, The University of Texas at San Antonio, and Hong Wang, University of North Texas, “Visualize Molecular Adsorption on Supported Ni-porphyrin Model Catalysts via Substitute Effect”

The Welch Postdoctoral Fellows of the Life Sciences Research Foundation provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas.

The foundation previously announced that it would name fellows from Rice University and Baylor University who would receive $100,000 annually for three years. This year's recipients and their research topics include:

  • Teng Yuan, Rice University, “Unlocking New Chemistry of Nonheme Iron Enzymes for α-Amino Acids and γ-Lactones Synthesis”
  • Katelyn Baumler, Baylor University, "Crystal Growth of Ln2Fe4Sb5 Phases Toward the Study of Novel Quantum Properties”

“As these programs become more established, it is thrilling to see the new research our awardees are exploring,” Adam Kuspa, president of The Welch Foundation, said in a news release. “The Foundation is very pleased by the applications that we continue to receive describing exciting new research projects to advance chemical research.”

This additional funding comes on the heels of the foundation doling out $27 million for chemical research, equipment and postdoctoral fellowships earlier this summer. The foundation made 85 grants to faculty at 16 Texas institutions at the time. Read more here.

How a Houston company is fighting anxiety, insomnia & Alzheimer’s through waveforms

mental health

A Houston-based company is taking a medicine-free approach to target brain neurologically associated with mental illness.

Nexalin Technology’s patented, FDA-cleared frequency-based waveform targets key centers of the midbrain to support the normalization of neurochemicals through a process known as Transcranial Alternating Current Stimulation (tACS). Delivered via a non-invasive device, the treatment gently stimulates the hypothalamus and midbrain, helping to “reset networks associated with symptoms” of anxiety and insomnia. Early clinical evidence suggests this approach can promote healthier brain function and improved sleep.

Through its recently appointed scientific advisory board (SAB), Nexalin also aims to target Alzheimer’s disease with a clinical development pipeline supported by published data and internal data from studies involving its proprietary DIFS technology. Nexalin’s Gen-2 SYNC and Gen-3 Halo headset delivers the DIFS, which is a waveform that can penetrate deep brain structures implicated in cognitive decline and mental illness.

The board includes experts in neurology, neuroimaging and neurodegenerative diseases with Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer coming on board. Nexalin plans to initiate new Alzheimer’s-focused clinical studies in the Q3 2025 by incorporating cognitive testing, imaging biomarkers, and guided metrics to assess treatment efficacy and neural activation.

“I am excited to work alongside Nexalin’s leadership and fellow SAB members to help guide the next generation of non-invasive neuromodulation therapies,” Huang said in a news release. “The intersection of neuroimaging, brain stimulation, and clinical science holds enormous potential for treating neurodegenerative disease.”

Recently, Nexalin’s proprietary neurostimulation device moved forward with a clinical trial that evaluated its treatment of anxiety disorders and chronic insomnia in Brazil. The first of Nexalin’s Gen-2 15-milliamp neurostimulation devices was shipped to São Paulo, Brazil, and the study will be conducted at the Instituto de Psiquiatria University Hospital (IPq-HCFMUSP). The shipments aim to support the launch of a Phase II clinical trial in adult patients suffering from anxiety and insomnia. The Nexalin Gen-2 15-milliamp neurostimulation device has also been approved in China, Brazil and Oman. Its Gen 1 device first received FDA clearance in 2003, according to the company's website.

The company also enrolled the first patients in its clinical trial at the University of California, San Diego, in collaboration with the VA San Diego Healthcare System for its Nexalin HALO, which looks to treat mild traumatic brain injury and post-traumatic stress disorder in military personnel and the civilian population.

Nexalin previously raised $5 million through a

public stock offering.

Houston innovation hub announces first cohort for energy-focused accelerator

Powering Up

Energytech Nexus, a Houston-based hub for energy startups, has named its inaugural cohort of 14 companies for the new COPILOT accelerator.

COPILOT partners with Browning the Green Space, a nonprofit that promotes diversity, equity and inclusion (DEI) in the clean energy and climatech sectors. The Wells Fargo Innovation Incubator (IN²) at the National Renewable Energy Laboratory backs the COPILOT accelerator.

The eight-month COPILOT program offers mentorship, training and networking for startups. Program participants will be tasked with developing pilot projects for their innovations.

Two Houston startups are members of the first COPILOT class:

  • GeoFuels, housed at Houston’s Greentown Labs, has come up with a novel approach to hydrogen production that relies on geothermal power and methane decomposition.
  • PolyQor, which converts plastic waste into eco-friendly construction materials. Its flagship EcoGrete product is an additive for concrete that enhances its properties while reducing carbon emissions. PolyQor’s headquarters is at Houston’s Greentown Labs.

Other members of the COPILOT cohort are:

  • Birmingham, Alabama-based Accelerate Wind, developer of a wind turbine for commercial buildings.
  • Ann Arbor, Michigan-based Aquora Biosystems, which specializes in organic waste biorefineries.
  • Phoenix-based EarthEn Energy, a developer of technology for thermo-mechanical energy storage.
  • New York City-based Electromaim, which installs small hydro-generators in buildings’ water systems.
  • Chandler, Arizona-based EnKoat, an advanced materials company whose flagship product, the IntelliKoat System, is a patented two-layer thermal and weather barrier roof coating for flat and low-slope commercial buildings.
  • Calgary, Canada-based Harber Coatings, which manufactures electroless nickel coating and electroless nickel plating.
  • Dallas-based Janta Power, which designs and makes 3D solar towers.
  • Miami-based NanoSieve, a developer of gas remediation technology.
  • Palo Alto, California-based Popper Power, which has developed a platform that turns streetlight networks into resilient, maintenance-free distributed charging infrastructure.
  • Buffalo, New York-based Siva Powers America, developer of small wind turbines for farms, utility companies and others with annual energy needs of 300,000 to 2 million kilowatt-hours.
  • Los Angeles-based Thermoshade, which specializes in cooling panels for outdoor environments.
  • Waukesha, Wisconsin-based V-Glass, Inc., developer of a vacuum-insulated glass for affordable high-efficiency windows.

“These startups reflect the future of energy access and resilience innovation,” said Juliana Garaizar, founding partner of Energytech Nexus. “By connecting them directly with partners through COPILOT, we’re helping them overcome the ‘pilot gap’ to build solutions that scale.”

The startups will run pilot projects along the Gulf Coast for their inventions.